Nastilox (Clopidogrel)

Clopidogrel, the active ingredient in Nastilox, is a P2Y12 receptor antagonist (antiplatelet agent) presented as an oral tablet for oral use. It helps prevent atherothrombotic events in patients who have experienced a recent myocardial infarction, stroke, or who have established peripheral arterial disease, and it is also used after acute coronary syndrome and percutaneous coronary intervention. GNH USA supplies Nastilox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clopidogrel acts on platelet aggregation pathways to reduce thrombotic risk in cardiovascular disease. - Acute coronary syndrome: lowers the chance of recurrent myocardial infarction or death. - Post‑percutaneous coronary intervention (PCI): provides antiplatelet protection to prevent stent thrombosis. - Established peripheral arterial disease, recent myocardial infarction or stroke: reduces incidence of atherothrombotic events.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums - Easy bruising - Nausea - Diarrhea - Headache - Rash

Serious or Rare Side Effects: - Severe bleeding (intracranial or gastrointestinal) - Thrombotic thrombocytopenic purpura (TTP) - Allergic reactions such as angioedema or anaphylaxis - Hepatotoxicity - Neutropenia

Before prescribing or dispensing clopidogrel, clinicians should consider several safety measures. - Assess bleeding risk: review patient history of hemorrhage or coagulopathy. - Monitor platelet function: consider laboratory testing in patients with liver disease. - Avoid use in active pathological bleeding: discontinue if significant bleeding occurs. - Caution in surgery or invasive procedures: stop according to procedural guidelines. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clopidogrel interacts with several drug classes that can modify its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid): - Oral anticoagulants (warfarin, DOACs): heightened risk of major bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs, aspirin): additive hemorrhagic effect. - Proton pump inhibitors (omeprazole, esomeprazole): may reduce clopidogrel activation.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (fluoxetine, fluvoxamine): may increase clopidogrel plasma levels. - CYP2C19 inducers (rifampin, carbamazepine): may reduce antiplatelet efficacy. - Statins (atorvastatin, simvastatin): potential pharmacokinetic interaction requiring monitoring.